Brokerages Anticipate AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $87.80 Million
Equities research analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to post $87.80 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for AngioDynamics’ earnings. The highest sales estimate is $88.41 million and the lowest is $87.30 million. AngioDynamics posted sales of $89.03 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.4%. The company is expected to report its next quarterly earnings results on Friday, January 5th.
According to Zacks, analysts expect that AngioDynamics will report full-year sales of $87.80 million for the current financial year, with estimates ranging from $352.20 million to $355.78 million. For the next financial year, analysts anticipate that the company will post sales of $363.52 million per share, with estimates ranging from $361.78 million to $366.77 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The business had revenue of $85.40 million for the quarter, compared to the consensus estimate of $86.12 million. During the same period in the previous year, the company posted $0.17 earnings per share. AngioDynamics’s revenue for the quarter was down 3.1% compared to the same quarter last year.
Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of AngioDynamics by 14.4% in the second quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock valued at $31,416,000 after buying an additional 243,825 shares in the last quarter. Broadfin Capital LLC grew its stake in shares of AngioDynamics by 14.9% in the second quarter. Broadfin Capital LLC now owns 1,683,252 shares of the medical instruments supplier’s stock valued at $27,286,000 after buying an additional 217,800 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of AngioDynamics by 49.4% in the third quarter. Janus Henderson Group PLC now owns 1,439,873 shares of the medical instruments supplier’s stock valued at $24,607,000 after buying an additional 476,327 shares in the last quarter. Northern Trust Corp grew its stake in shares of AngioDynamics by 14.9% in the second quarter. Northern Trust Corp now owns 1,202,941 shares of the medical instruments supplier’s stock valued at $19,500,000 after buying an additional 155,951 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of AngioDynamics by 0.9% in the third quarter. Wells Fargo & Company MN now owns 1,025,233 shares of the medical instruments supplier’s stock valued at $17,521,000 after buying an additional 9,639 shares in the last quarter. 96.21% of the stock is owned by institutional investors and hedge funds.
Shares of AngioDynamics (NASDAQ ANGO) opened at $17.35 on Friday. AngioDynamics has a 52 week low of $14.80 and a 52 week high of $18.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.48 and a current ratio of 2.34. The stock has a market capitalization of $636.65, a P/E ratio of 25.13, a P/E/G ratio of 1.78 and a beta of 1.05.
ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $87.80 Million” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/25/brokerages-anticipate-angiodynamics-inc-ango-will-announce-quarterly-sales-of-87-80-million.html.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.